Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk

Detalles Bibliográficos
Autores principales: Hartung, Hans-Peter, Mares, Jan, Meuth, Sven G., Berger, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609079/
https://www.ncbi.nlm.nih.gov/pubmed/34480292
http://dx.doi.org/10.1007/s13311-021-01102-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609079/
https://www.ncbi.nlm.nih.gov/pubmed/34480292
http://dx.doi.org/10.1007/s13311-021-01102-w

Ejemplares similares